Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
Harrow Health, Inc. (NASDAQ: HROW) announced the release of its financial results for Q2 and six months ended June 30, 2021, scheduled for August 10, 2021, post-market. The company will share its second-quarter letter to stockholders on its website. A conference call and live webcast will follow at 4:45 PM ET to discuss results and provide a business update. Harrow Health is focused on ophthalmology, operating ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
- Scheduled release of Q2 financial results may indicate stable financial reporting.
- Company continues to operate two strong subsidiaries: ImprimisRx and Visionology.
- Harrow Health has equity interests in emerging pharmaceutical companies.
- None.
NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.
| Conference Call Details: | |
| Date: | Tuesday, August 10, 2021 |
| Time: | 4:45 p.m. Eastern time |
| Participant Dial-in: | 1-833-953-2434 (U.S.) 1-412-317-5763 (International) |
| Replay Dial-in (Passcode 10157937): (telephonic replay through August 17, 2021) | 1-877-344-7529 (U.S.) 1-412-317-0088 (International) |
| Webcast: (online replay through November 10, 2021) | harrowinc.com |
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.
Contact:
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737
FAQ
When will Harrow Health release its Q2 2021 financial results?
What time is the Harrow Health conference call to discuss Q2 results?
Where can I find Harrow Health's letter to stockholders?
What subsidiaries does Harrow Health operate?
